passages: 3592
passages: document
passages: EORTC protocols in prostatic cancer . An interim report . Two parallel prospective randomized studies have been undertaken by the EORTC Urological Group in previously untreated patients with prostatic cancer in order to compare low dose Stilboestrol versus Cyproterone acetate versus Medroxyprogesterone acetate in the first trial , and Stilboestrol versus Estracyt in the second trial . Although the follow up is still short , no superiority of the other drugs over Stilboestrol had appeared so far with regard to either objective response or significant side effects apart from gynaecomastia . In the third trial , patients with advanced disease no longer responsive to hormonal treatment were randomized to either Adriamycin or Procarbazine . Toxicity and early death were particularly frequent in Procarbazine treated patients , whereas most patients progressed in both treatment groups .
entities: 3593
entities: Intervention_Pharmacological
entities: Stilboestrol
entities: 3594
entities: Intervention_Pharmacological
entities: Cyproterone acetate
entities: 3595
entities: Intervention_Pharmacological
entities: Medroxyprogesterone acetate
entities: 3596
entities: Intervention_Pharmacological
entities: Stilboestrol
entities: 3597
entities: Intervention_Pharmacological
entities: Estracyt
entities: 3598
entities: Intervention_Pharmacological
entities: Stilboestrol
entities: 3599
entities: Intervention_Pharmacological
entities: Adriamycin
entities: 3600
entities: Intervention_Pharmacological
entities: Procarbazine .
entities: 3601
entities: Intervention_Pharmacological
entities: Procarbazine
entities: 3602
entities: Outcome_Adverse-effects
entities: side effects
entities: 3603
entities: Outcome_Adverse-effects
entities: gynaecomastia
entities: 3604
entities: Outcome_Physical
entities: .
entities: 3605
entities: Outcome_Mortality
entities: Toxicity and early death
entities: 3606
entities: Participant_Condition
entities: prostatic cancer .
entities: 3607
entities: Participant_Condition
entities: previously untreated patients with prostatic cancer
entities: 3608
entities: Participant_Condition
entities: patients with advanced disease no longer responsive to hormonal treatment